SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 2 | February 2024 - Peer Reviewed Journal

NANOPARTICLE-BASED APPROACHES FOR mRNA DELIVERY: A COMPREHENSIVE REVIEW

Shubham Singh*, Dr. Arun Patel, Shailendra Patel, Vijay Pratap Ahirwar
Shri Ram Group of Institution, Faculty of Pharmacy, Jabalpur

ABSTRACT
The advent of mRNA-based therapies has revolutionized the field of medicine, offering promising solutions for various diseases, including cancer, infectious diseases, and genetic disorders. However, the efficient delivery of mRNA molecules to target cells remains a significant challenge. Nanoparticle-based approaches have emerged as a versatile and effective strategy to overcome the obstacles associated with mRNA delivery. This comprehensive review explores the current state of nanoparticle-based approaches for mRNA delivery, highlighting key advancements, challenges, and future prospects.

KEY WORDS: *mRNA, revolutionized, efficient delivery, nanoparticle-based approaches.*

INTRODUCTION

The field of mRNA therapeutics has experienced significant growth in recent years, opening up new possibilities for the treatment of various diseases. However, the efficient delivery of mRNA remains a critical challenge. Nanoparticle-based approaches have emerged as promising solutions to overcome these obstacles and enhance the efficacy of mRNA delivery. This article reviews recent advancements in nanoparticle-mediated mRNA delivery, highlighting key studies and breakthroughs in the field. mRNA therapeutics hold immense potential for precision medicine, enabling the modulation of gene expression to treat and prevent a wide range of diseases. Nevertheless, the delivery of mRNA faces hurdles such as rapid degradation, low cellular uptake, and immunogenicity. Nanoparticle-based delivery systems offer a promising avenue to address these challenges and enhance the therapeutic potential of mRNA.In summary, nanoparticle-based approaches for mRNA delivery offer several advantages, including enhanced stability, improved cellular uptake, targeted delivery, and controlled release. However, challenges such as immunogenicity, off-target effects, toxicity, and regulatory considerations must be carefully addressed to ensure the safety and efficacy of these delivery systems in clinical settings.

The emergence of messenger RNA (mRNA) therapeutics has revolutionized the landscape of medicine, offering a promising avenue for the treatment of various diseases, including cancer, genetic disorders, and infectious diseases. Unlike traditional small molecule drugs or protein-based therapies, mRNA therapeutics enable the direct modulation of intracellular protein expression, providing unprecedented precision and flexibility in therapeutic interventions. However, the successful translation of mRNA-based therapies into clinical applications hinges upon overcoming significant hurdles in delivery to target cells.One of the foremost challenges in mRNA therapeutics is ensuring efficient delivery to the desired cellular compartments while protecting the fragile mRNA molecules from degradation by extracellular nucleases and immune recognition. Nanoparticle-based delivery systems have emerged as a versatile and effective strategy to address these challenges, offering a multifaceted approach to enhance the stability, cellular uptake, and targeted delivery of mRNA payloads.

Nanoparticles, defined as particles with dimensions ranging from 1 to 100 nanometers, possess unique physicochemical properties that make them well-suited for the delivery of therapeutic payloads, including mRNA. These properties include a high surface area-to-volume ratio, tunable surface chemistry, and the ability to encapsulate or conjugate therapeutic agents. By leveraging these properties, nanoparticle-based delivery systems can protect mRNA from degradation, facilitate cellular uptake, promote endosomal escape, and enable targeted delivery to specific tissues or cell types.[26]

New drugs using mRNA should offer new and innovative solutions for the treatment of diseases previously thought to be difficult or incurable. However, it is difficult for mRNA to complete its job on its own. [22] The negative charge of this large biomolecule prevents it from entering cell membranes. Additionally, its single-stranded structure is subject to degradation, especially in ribonuclease-rich physiological conditions in the body. To this end, the development of mRNA drugs largely relies on the design of delivery vehicles to overcome biological barriers and efficiently transport mRNA into the cytoplasm for protein production. [23,24]

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 2 | February 2024 - Peer Reviewed Journal

TYPES OF NANOPARTICLES

Lipid Nanoparticles (LNPs)

Lipid nanoparticles represent one of the most widely studied and successful platforms for mRNA delivery. Comprising cationic lipids, neutral lipids, and polyethylene glycol (PEG), LNPs can encapsulate and protect mRNA, facilitate cellular uptake, and enable endosomal escape. Recent studies have demonstrated the efficacy of LNPs in delivering mRNA payloads for applications ranging from cancer immunotherapy to infectious disease vaccines.[1], [2], [3].

Polymer-Based Nanoparticles

Polymer-based nanoparticles, such as polyethyleneimine (PEI) and poly(lactic-co-glycolic acid) (PLGA), offer unique advantages for mRNA delivery. These nanoparticles can be tailored for controlled release and exhibit a high payload capacity. Additionally, surface modifications can enhance their biocompatibility and target-specific delivery.[4], [5], [6].

Inorganic Nanoparticles:

Inorganic nanoparticles, including gold nanoparticles and silica nanoparticles, have shown promise in mRNA delivery due to their unique physicochemical properties. Surface modifications and functionalization allow for improved stability and cellular uptake. However, concerns regarding toxicity and long-term effects warrant further investigation.[7], [8], [9].



Figure: mRNA-based vaccine Nano-delivery systems

Nanoparticle Formulations for mRNA Delivery

Nanoparticles play a crucial role in protecting mRNA from degradation, facilitating cellular uptake, and promoting controlled release. Lipid nanoparticles (LNPs) and polymeric nanoparticles are among the most widely explored carriers for mRNA delivery. Notably,

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 2 | February 2024 - Peer Reviewed Journal

studies have demonstrated the successful use of LNPs in delivering mRNA to target cells, achieving high transfection efficiency with low cytotoxicity.[10],[11]

Surface Modification and Targeting

To enhance the specificity and efficiency of mRNA delivery, surface modifications of nanoparticles are being explored. Functionalization with targeting ligands, such as antibodies or peptides, allows for the selective delivery of mRNA to specific cells or tissues. The work of Sun et al. (2019) exemplifies the successful use of targeted LNPs for mRNA delivery to cancer cells, resulting in improved therapeutic outcomes.[12]

Biocompatibility and Safety Considerations

Safety is a paramount concern in nanoparticle-based mRNA delivery systems. Ensuring biocompatibility and minimizing off-target effects are critical for the translation of these technologies into clinical applications. The study highlights the importance of biodegradable nanoparticles in minimizing potential long-term side effects, paving the way for safer mRNA therapeutics.[13]

Advantages

Enhanced Stability and Protection

Nanoparticles provide a protective shield for mRNA molecules, preventing degradation by nucleases and enzymatic activities. This enhanced stability ensures the preservation of the therapeutic payload during transport to the target cells. [14]

Improved Cellular Uptake

Nanoparticles facilitate efficient cellular uptake of mRNA by promoting endocytosis or direct fusion with cell membranes. Surface modifications can enhance the interaction with cell receptors, promoting internalization and improving overall delivery efficiency. [15]

Targeted Delivery

Functionalization of nanoparticles allows for targeted delivery to specific tissues or cells. Ligands or antibodies can be conjugated to the nanoparticle surface, enabling site-specific delivery and minimizing off-target effects. [16]

Controlled Release

Nanoparticles can be engineered to enable controlled release of mRNA, providing sustained therapeutic effects. This feature allows for the modulation of gene expression over time, enhancing the overall efficacy of mRNA-based therapies.[17]

Disadvantages

Immunogenicity

Nanoparticles themselves may trigger immune responses, leading to potential adverse effects. Surface modifications and proper selection of materials are critical to minimize immunogenic reactions and ensure the safety of the delivery system. [18]

Off-Target Effects

Despite efforts to achieve targeted delivery, nanoparticles may still interact with unintended cells or tissues, leading to off-target effects. This can result in undesired side effects and impact the overall safety profile of the mRNA delivery system. [19]

Toxicity Concerns

Certain nanoparticle materials may exhibit inherent toxicity, raising concerns about their long-term safety. Understanding the biocompatibility of nanoparticles and conducting thorough toxicity assessments are essential for clinical translation. [20]

Regulatory Challenges

The regulatory approval process for nanoparticle-based mRNA delivery systems involves addressing unique challenges, such as characterizing the complex interactions between nanoparticles and biological systems. This can result in delays in the translation of these technologies to clinical applications. [21]

Challenges and Considerations

Despite significant progress, challenges persist in the development of nanoparticle-based mRNA delivery systems. Issues such as immunogenicity, off-target effects, and scalability need to be addressed for widespread clinical adoption. Ongoing research focuses on

SJIF Impact Factor (2024): 8.675| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 9 | Issue: 2 | February 2024 - Peer Reviewed Journal

optimizing nanoparticle formulations, improving delivery kinetics, and developing innovative strategies to overcome these challenges. Addressing these issues is crucial for the successful translation of nanoparticle-based mRNA therapies from preclinical to clinical settings.

Future Perspectives

The ongoing research in nanoparticle-based mRNA delivery holds promise for groundbreaking advancements in personalized medicine. Future developments may include the design of multifunctional nanoparticles, optimization of delivery kinetics, and the exploration of novel materials for improved safety and efficacy.

CONCLUSION

Nanoparticle-based approaches for mRNA delivery represent a dynamic and promising field in therapeutic development. The studies highlighted in this review underscore the potential of nanoparticles in enhancing mRNA stability, promoting targeted delivery, and ensuring biocompatibility. As researchers continue to innovate and refine these delivery systems, the translation of mRNA therapeutics from the bench to the bedside becomes increasingly feasible. Continued interdisciplinary efforts are essential to unlock the full potential of mRNA therapies and bring them into mainstream clinical practice.In this review, we will explore the current state of nanoparticle-based approaches for mRNA delivery, highlighting key advancements, challenges, and future prospects in this rapidly evolving field. By understanding the intricacies of nanoparticle-mediated mRNA delivery, researchers and clinicians can harness the full potential of mRNA therapeutics and pave the way for transformative innovations in precision medicine.

REFERENCES

1. *Smith A, et al. Lipid Nanoparticles for mRNA Delivery. Nat Rev Drug Discov. 2020;19(12):874-888.*
2. *Pardi N, et al. mRNA Vaccines - a New Era in Vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279.*
3. *Sahin U, et al. Advances and Challenges in the Development of mRNA Vaccines. Npj Vaccines. 2021;6(1):1-10.*
4. *Akinc A, et al. A Combinatorial Library of Lipid-Like Materials for Delivery of RNAi Therapeutics. Nat Biotechnol. 2008;26(5):561-569.*
5. *Cheng R, et al. Development of Nanoparticles for Anticancer Drug Delivery. Curr Med Chem. 2013;20(26):327-347.*
6. *Xu X, et al. Poly(lactic-co-glycolic acid)-based Nanoparticles for RNAi-Mediated Gene Silencing in Nervous System Disorders. Biomaterials. 2019;203:35-47.*
7. *Jokerst JV, et al. Nanoparticle PEGylation for Imaging and Therapy. Nanomedicine (Lond). 2011;6(4):715-728.*
8. *Dreaden EC, et al. Nanoparticle Drug Conjugates for Cancer Chemotherapy. Mol Pharm. 2012;9(9):2350-2367.*
9. *Wang Y, et al. Gold Nanoparticles-mediated siRNA Delivery for Targeting Oncogenes in Cancer. Adv Therap. 2019;2(11):1900144.*
10. *Pardi, N., Hogan, M. J., Porter, F. W., &Weissman, D. (2018). mRNA vaccines—A new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261-279.*
11. *Kulkarni, J. A., Witzigmann, D., Leung, J., Tam, Y. K., &Cullis, P. R. (2020). On the road to in vivo biomolecule delivery: A microenvironment-dependent trade-off between permeability and retention of nanocarriers. Advanced Drug Delivery Reviews, 157, 78-90.*
12. *Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., &Gu, Z. (2019). Self-assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing. AngewandteChemie International Edition, 58(41), 14991-14996.*
13. *Chen, Y., Zhang, Y., Chen, M., Zhuang, H., & Yang, Y. (2021). Nanoparticles-mediated mRNA delivery for therapeutic applications: Progress and challenges. Journal of Nanobiotechnology, 19(1), 161.*
14. *Kanasty R, et al. (2013) Delivery of siRNA to the target cell in a cell-specific manner, Nat Rev Drug Discov, 12(6): 492-508.*
15. *Akinc A, et al. (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics, Nat Biotechnol, 26(5): 561-569.*
16. *Ashley CE, et al. (2011) The targeted delivery of multicomponent cargos to cancer cells by nano-porous particle-supported lipid bilayers, Nat Mater, 10(5): 389-397.*
17. *Sunshine J, et al. (2011) Nano-structured gene carriers, Gene Ther, 18(7): 671-678.*
18. *Dobrovolskaia MA, et al. (2008) Immunological properties of engineered nanomaterials, Nat Nanotechnol, 2(8): 469-478.*
19. *Hrkach J, et al. (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile, SciTransl Med, 4(128): 128ra39.*
20. *Nel AE, et al. (2006) Toxic potential of materials at the nanolevel, Science, 311(5761): 622-627.*
21. *Sahoo SK, et al. (2007) The regulatory role of nanotechnology in drug development, Pharm Res, 24(8): 1661-1677.*
22. *S. Kreiter, M. Diken, A. Selmi, J. Diekmann, S. Attig, Y. Husemann, M. Koslowski, C. Huber, O. Tureci, U. Sahin, FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines, Cancer Res., 71 (2011), pp. 6132-6142*
23. *J. Conde, R. Langer, J. Rueff , mRNA therapy at the convergence of genetics and nanomedicine Nat. Nanotechnol. (2023), pp. 1-4*
24. *S.F. Dowdy, Overcoming cellular barriers for RNA therapeutics, Nat. Biotechnol., 35 (2017), pp. 222-229*
25. *Weng, Y.; Li, C.; Yang, T.; Hu, B.; Zhang, M.; Guo, S.; Xiao, H.; Liang, X.-J.; Huang, Y. The challenge and prospect of mRNA therapeutics landscape. Biotechnol. Adv.* **2020**, *40, 107534.*
26. *Li Y, et al. (2019) RNA Nanotechnology-Mediated Cancer Immunotherapy. Theranostics, 9(26): 8006-8023.*